Armstrong, Victor William

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Brandhorst, Gunnar"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Petrova, Darinka Todorova"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, M."],["dc.date.accessioned","2018-11-07T11:24:07Z"],["dc.date.available","2018-11-07T11:24:07Z"],["dc.date.issued","2009"],["dc.format.extent","664"],["dc.identifier.isi","000270484600225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","11th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology"],["dc.relation.eventlocation","Montreal, CANADA"],["dc.relation.issn","0163-4356"],["dc.title","Mycophenolate Mofetil improves Kidney Function but not Survival in a COL4A3-deficient Mouse Model for Progressive Renal Fibrosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Pediatric Nephrology"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Weber, Lutz T."],["dc.contributor.author","Hoecker, Britta"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Toenshoff, Burkhardt"],["dc.date.accessioned","2018-11-07T10:59:19Z"],["dc.date.available","2018-11-07T10:59:19Z"],["dc.date.issued","2007"],["dc.format.extent","1446"],["dc.identifier.isi","000247977300169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50670"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0931-041X"],["dc.title","Long-term (3 years) pharmacokinetics (PK) of mycophenolic acid (MPA) in pediatric renal transplant recipients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","20"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","26"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Schutz, Ekkehard"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Weber, Lutz T."],["dc.contributor.author","Tonshoff, B."],["dc.contributor.author","Armstrong, Victor William"],["dc.date.accessioned","2018-11-07T10:55:24Z"],["dc.date.available","2018-11-07T10:55:24Z"],["dc.date.issued","2000"],["dc.description.abstract","The need for mycophenolic acid (MPA) monitoring is still under discussion. Key issues for the PK/PD relationships of this drug are: the role of metabolites, the usefulness of AUC versus predose levels, and the need to monitor the free concentration of MPA (f-MPA). Recent advances have revealed that, in addition to 7-O-MPAG, three additional MPA metabolites are present in the plasma of transplant recipients. One of these metabolites (M-2), identified as an acyl glucuronide of MPA, was found to inhibit IMPDH-II in vitro. This active metabolite was also found to cross-react in the Emit assay for MPA. In an ongoing multicenter study, the authors are evaluating the relevance of monitoring total (t-MPA) and free mycophenolic acid (f-MPA) in pediatric renal transplant recipients. As in adults, a time-dependant increase of t-MPA-AUC(0-12h) within the first 3 months posttransplant (35 versus 64 mg x L/h, 3 weeks versus 3 months respectively; daily dosage: 0.6 g/m(2) bid) was seen. Receiver operating characteristics curve analyses were used to test the ability of predose levels or AUC(0-12h) to discriminate between cases with no complications and those with acute rejection, adverse events (severe infections, leukopenia), or gastrointestinal disorders observed during the early posttransplant course, In agreement with observations in adults, a significant (p = 0.001) association was observed between AUC(0-12h) and acute rejection. A t-MPA-AUC(0-12h) of approximately 30-60 mg x L/h, as determined by HPLC, seems to be a reasonable target for the early posttransplant period. It remains to be elucidated whether regular predose level monitoring may be of more practical value. A higher incidence of rejection was observed at predose MPA concentrations less than or equal to 1 mg/L, as measured by HPLC. In contrast to t-MPA, f-MPA-AUC(0-12h) was significantly related to seven infections and leukopenia. The risk for severe adverse events was increased at f-MPA- AUC(0-12h) values greater than or equal to 600 mu g x Uh. On the basis of these data and the observed variability in the pharmacokinetics of MPA, the development of monitoring strategies for this drug appears to he promising."],["dc.identifier.doi","10.1097/00007691-200002000-00004"],["dc.identifier.isi","000085149700004"],["dc.identifier.pmid","10688252"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49780"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0163-4356"],["dc.title","Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neurosciences"],["dc.bibliographiccitation.lastpage","271"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schenk-Daprá, Bettina"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Müller, Peter"],["dc.contributor.author","Niedmann, Paul Dieter"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Rüther, Eckart"],["dc.date.accessioned","2017-09-07T11:44:42Z"],["dc.date.available","2017-09-07T11:44:42Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective The goal of this study was to identify adverse effects of the atypical neuroleptic clozapine on liver function and lipid metabolism. Methods Data which included serum levels of clozapine and its hepatic metabolite N-desmethyl clozapine were collected from medical records of patients treated with clozapine and controls. Results We identified a clozapine-associated marked elevation of plasma cholinesterase (ChE) with unchanged levels of AST, ALT or g-GT. ChE was correlated to the serum level of clozapine and even closer to N-desmethyl clozapine. For the total patient group we observed significant correlations of ChE with the body-mass index and body weight. However, clozapine-treated patients and controls did not differ with regard to body-mass index, triglycerides, and cholesterol. Conclusion We report for the first time a clozapine-associated and dose-dependent elevation of plasma ChE, which may be related to clozapine-associated effects on hepatic lipid metabolism or ChE enzyme induction."],["dc.identifier.doi","10.1007/pl00007544"],["dc.identifier.gro","3151720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8541"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","0940-1334"],["dc.title","Clozapine-associated elevation of plasma cholinesterase"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","664A"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","665A"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Kiehl, M. G."],["dc.contributor.author","Schaefer-Eckart, K."],["dc.contributor.author","Kienast, J."],["dc.contributor.author","Jenke, A."],["dc.contributor.author","Wandt, Hannes"],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Basara, N."],["dc.contributor.author","Fauser, A. A."],["dc.contributor.author","Bornhaeuser, Martin"],["dc.date.accessioned","2018-11-07T11:24:06Z"],["dc.date.available","2018-11-07T11:24:06Z"],["dc.date.issued","2001"],["dc.identifier.isi","000172134102799"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56328"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.issn","0006-4971"],["dc.title","Randomized multicenter prospective clinical trial on the efficacy of mycophenolate mofetil in comparison to methotrexate for the prophylaxis of acute GvHD in stem cell transplant recipients."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1551"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Clinical Chemistry"],["dc.bibliographiccitation.lastpage","1552"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Oellerich, M."],["dc.date.accessioned","2018-11-07T10:36:24Z"],["dc.date.available","2018-11-07T10:36:24Z"],["dc.date.issued","2003"],["dc.identifier.isi","000184896200028"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45314"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Clinical Chemistry"],["dc.relation.issn","0009-9147"],["dc.title","Commentary on: Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods - Response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Pediatric Nephrology"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Feneberg, Reinhard"],["dc.contributor.author","Weber, Lutz T."],["dc.contributor.author","van Asen, N."],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Hoecker, Britta"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Toenshoff, Burkhardt"],["dc.date.accessioned","2018-11-07T10:59:19Z"],["dc.date.available","2018-11-07T10:59:19Z"],["dc.date.issued","2007"],["dc.format.extent","1588"],["dc.identifier.isi","000247977300735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50673"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0931-041X"],["dc.title","Consequences of CYP3A4 and MDR-1 polymorphisms on pharmakokinetic parameters of cyclosporin a and mycophenolic acid in pediatric renal transplantation recipients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Voland, A."],["dc.contributor.author","Grone, H. J."],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Wieland, Eberhard"],["dc.date.accessioned","2018-11-07T10:37:34Z"],["dc.date.available","2018-11-07T10:37:34Z"],["dc.date.issued","2003"],["dc.format.extent","537"],["dc.identifier.isi","000184445500220"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45598"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","8th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology"],["dc.relation.eventlocation","BASEL, SWITZERLAND"],["dc.relation.issn","0163-4356"],["dc.title","Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in Wistar rats treated with mycophenolate mofetil (MMF)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","297"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","304"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","El Desoky, E. S."],["dc.contributor.author","Abdelsalam, Y. M."],["dc.contributor.author","Salama, R. H."],["dc.contributor.author","El Akkad, M. A."],["dc.contributor.author","Atanasova, Srebrena"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, M."],["dc.date.accessioned","2018-11-07T10:58:59Z"],["dc.date.available","2018-11-07T10:58:59Z"],["dc.date.issued","2005"],["dc.description.abstract","Arylarnine N-acetyl transferase (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and genotoxic compounds such as amine carcinogens. To investigate whether the slow acetylator genotype is a risk factor for development of bladder cancer following schistosomal infection of the urinary tract, the authors determined the frequencies of 3 common polymorphisms in the NAT2 gene (341T > C, 590G > A, and 282C > T), which are associated with impaired acetylation activity, in control subjects (n = 61; mean age 34.3 +/- 9.2 years) and in schistosomiasis-associated bladder cancer patients (n = 55; 52 +/- 10.9 years) from the Egyptian population. Genotyping was carried out using rapid cycle PCR on the LightCycler, and subjects were assigned to a slow, intermediate, or rapid acetylator phenotype on the basis of the genotypes. The frequencies of the mutant alleles observed in the controls from the present study were similar to those reported previously for both the Egyptian population and other Arab populations. Patients showed a higher prevalence (78.2%) of slow acetylator phenotype than controls (67.2%), but this did not reach statistical significance (P = 0.19). However, there were significantly more individuals who were carriers of 2 mutant 341T > C alleles (NAT2 5/ 5 genotype) in the patient group compared with controls (odds ratio 2.6, CI 1.02-6.67, P = 0.026). The alloenzyme encoded by this allele has been shown to display a large reduction in its catalytic activity. In conclusion, these data suggest that the NAT2 5/ 5 genotype is a potential risk factor for development of urinary bladder cancer in patients with prior schistosomiasis infection."],["dc.identifier.doi","10.1097/01.ftd.0000164197.95494.aa"],["dc.identifier.isi","000229592500009"],["dc.identifier.pmid","15905799"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50593"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0163-4356"],["dc.title","NAT2 5/ 5 genotype (341T > C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2127"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Transplantation Proceedings"],["dc.bibliographiccitation.lastpage","2128"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Braun, F."],["dc.contributor.author","Schutz, Ekkehard"],["dc.contributor.author","Peters, B."],["dc.contributor.author","Talaulicar, R."],["dc.contributor.author","Grupp, Clemens"],["dc.contributor.author","Undre, N."],["dc.contributor.author","Schafer, A."],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Ringe, B."],["dc.date.accessioned","2018-11-07T09:09:13Z"],["dc.date.available","2018-11-07T09:09:13Z"],["dc.date.issued","2001"],["dc.identifier.doi","10.1016/S0041-1345(01)01970-4"],["dc.identifier.isi","000168781300016"],["dc.identifier.pmid","11377473"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26209"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","4th International Conference on New Trends in Clinical and Experimental Immunosuppression"],["dc.relation.eventlocation","GENEVA, SWITZERLAND"],["dc.relation.issn","0041-1345"],["dc.title","Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]